Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer Journal Article

   

Authors:	Hashimoto, T.; Krishnan, R.; Takeda, T.; Benfante, N.; Mulhall, J. P.; Hricak, H.; Eastham, J. A.; Vargas, H. A.
Article Title:	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer
Abstract:	Objective To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. Methods We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. Results After TRT, there was a significant increase in serum testosterone (516.5 ng/dl vs. 203.0 ng/dl), PSA (4.2 ng/ml vs. 3.3 ng/ml), and prostate volume (55.2 cm3 vs. 39.4 cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). Conclusions After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy. © 2016 Elsevier Inc.
Keywords:	prostate cancer; active surveillance; testosterone replacement therapy; testosterone deficiency; multiparametric prostate magnetic resonance imaging
Journal Title:	Urologic Oncology: Seminars and Original Investigations
Volume:	34
Issue:	12
ISSN:	1078-1439
Publisher:	Elsevier Inc.
Date Published:	2016-12-01
Start Page:	530.e9
End Page:	530.e14
Language:	English
DOI:	10.1016/j.urolonc.2016.07.004
PROVIDER:	scopus
PUBMED:	27665357
PMCID:	PMC5434455
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994410090&partnerID=40&md5=e936b0a4cddf4d90883c2a886af87318
Notes:	Article -- Export Date: 6 December 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/101439